



Journal of Cystic Fibrosis

The Official Journal of the European Cystic Fibrosis Society

Supplement:

Abstracts of the
44th European Cystic Fibrosis Conference – 2021
9–12 June 2021

Volume 20 Suppl. 1
ISSN 1569-1993

*Publication of this Abstract Book was supported by the European Cystic
Fibrosis Society*

www.ECFS.eu



bronchiolitis. Moreover, history of smoking by a household member and family history of allergy were recorded.

Results: Among the 160 newborns who presented to our clinic after newborn screening for CF, 117 (58.1%) could be contacted by phone. Cystic fibrosis was diagnosed in 6 (3.8%) of these subjects and 4 (2.5%) reported having had lower respiratory problems such as ever-wheezing, recurrent wheezing and pneumonia. Two children had died due to non-specified reasons. Smoking by a household member was reported in 33.8% of the parents and the prevalence of family history of allergy was 6.9%.

Conclusion: Frequency of every-wheezing in the first three years of life is about 20% in our community; thus the results of our study do not show an increase in respiratory problems with high IRT levels. However, follow up of these children for longer period of time for respiratory diseases is needed for more confident interpretations.

P015

Evaluation of the specificity and sensitivity of the cut-off values of immunoreactive trypsinogen in the cystic fibrosis newborn screening program

T. Ramasli Gursoy¹, P. Asfuroglu¹, T. Sismanlar Eyuboglu¹, A.T. Aslan¹, A.I. Yilmaz², G. Unal², B.S. Kibar², S. Pekcan², M. Hangul³, M. Kose³, I.I. Budakoglu⁴, D. Acican⁵. ¹Gazi University Faculty of Medicine, Pediatric Pulmonology, Ankara, Turkey; ²Necmettin Erbakan University Meram Faculty of Medicine, Pediatric Pulmonology, Konya, Turkey; ³Erciyes University Faculty of Medicine, Pediatric Pulmonology, Kayseri, Turkey; ⁴Gazi University Faculty of Medicine, Medical Education, Ankara, Turkey; ⁵Public Health General Directorate, Child and Adolescent Health, Ankara, Turkey

Objectives: Cystic fibrosis (CF) newborn screening (NBS) programme with the two-stage immunoreactive trypsinogen (IRT/IRT) protocol was included in the screening programme in 2015 in Turkey. If the first IRT is 90 µg/L and above and the second IRT is 70 µg/L and above, the screening test is considered positive and the patient is referred to the CF centres for a sweat chloride test. Each country determines their own cut-off values for IRT. We aimed to evaluate cut-off values and to determine the specificity and sensitivity of them in current NBS.

Methods: The data of children with positive NBS between 2015 and 2020 were evaluated retrospectively in three paediatric pulmonology centres. Patients' age at diagnosis, genders, IRT values and sweat chloride test results were noted. The sensitivity and specificity of the IRT cut-off values were evaluated.

Results: In total, 1,122 children admitted to paediatric pulmonology centers with positive NBS. 58 (5.1%) patients were diagnosed with CF. 29 (50%) patients with CF were female. The median age at diagnosis of the patients was 44 (IQR:30–72) days. The median of the first IRT values was 105.0 (IQR:94.0–195.2) and of the second IRT values was 80.0 (IQR: 61.8–95.0) in the CF patients. The median of the first sweat chloride test results was 75.0 (IQR: 72.0,95.0), of the second sweat chloride test results was 67.6 (IQR: 47.8, 90.6). When the cut-off value of the first IRT was 101.87 µg/L, the sensitivity was 81% and the specificity was 46%. When the cut-off value of the second IRT was 76.9 µg/L, the sensitivity was 82.8% and the specificity was 42.3%.

Conclusions: The detection power of screening tests is related to the cut-off value determined for the test. We found that the cut-off values we use in our country are effective in detecting the disease. The diagnostic power of IRT cut-off values may be evaluated periodically with multicentre studies.

P016

The role of clinical and laboratory findings in the diagnosis of cystic fibrosis in children with positive newborn screening

P. Asfuroglu¹, T. Ramasli Gursoy¹, T. Sismanlar Eyuboglu¹, A.T. Aslan¹, G. Unal², A.I. Yilmaz², B.S. Kibar², S. Pekcan², M. Hangul³, M. Kose³, I.I. Budakoglu⁴. ¹Gazi University Faculty of Medicine, Pediatric Pulmonology, Ankara, Turkey; ²Necmettin Erbakan University Meram Faculty of Medicine, Pediatric Pulmonology, Konya, Turkey; ³Erciyes University Faculty of Medicine, Pediatric Pulmonology, Kayseri, Turkey; ⁴Gazi University Faculty of Medicine, Medical Education, Ankara, Turkey

Objectives: In newborn screening (NBS) of cystic fibrosis (CF), the diagnosis may be delayed due to difficulty in accessing the sweat test. The importance of laboratory and clinical findings in suggesting

the diagnosis of CF was evaluated in children presenting with positive NBS.

Methods: The data of all children with positive NBS in three paediatric pulmonology departments between 2015 and 2020 were evaluated retrospectively. Children's age at admission and diagnosis, gender, parental consanguinity, daily weight gain, steatorrhea, clinical and laboratory findings were noted, the specificity and sensitivity of the clinical and laboratory findings of children were evaluated.

Results: A total of 1,141 children admitted to paediatric pulmonology departments with positive NBS were included, and 55.6% of them were female. The median age of children at admission was 27 (IQR: 21–35) days, and 59 (5.2%) patients were diagnosed with CF. The median age of patients at diagnosis was 43 (IQR: 30–71.5) days. Parental consanguinity was found in 193 (16.9%) children, 14 (1.2%) of whom were CF (specificity: 95.3%, sensitivity: 7.3%). Meconium ileus was present in 6 (0.5%) children, 2 (0.2%) of whom were CF (specificity: 99.4%, sensitivity: 9.1%). Doll-like face was found in 22 (1.9%) children, 18 (1.6%) of whom were CF (specificity: 99.6%, sensitivity: 33.3%). Metabolic alkalosis was found in 63 (5.5%) children, 16 (1.4%) of whom were CF (specificity: 91.8%, sensitivity: 30.8%). Steatorrhea was present in 181 (15.9%) children, 27 (2.3%) of whom were CF (specificity: 79.5%, sensitivity: 58.7%). There was a statistically significant difference in daily weight gain, pH, HCO₃, sodium, potassium, chloride, and albumin levels between children with and without CF (p < 0.05).

Conclusions: Doll-like face, meconium ileus, parental consanguinity, and metabolic alkalosis are powerful guides for the diagnosis of CF, since children with positive NBS may have difficulty in accessing the sweat tests.

P017

Different ethnic distribution of the incidence of cystic fibrosis in Republic of North Macedonia


V. Anastasovska¹, S. Fustik², M. Pesevska¹, N. Fakovic³, A. Stamatova². ¹University Clinic for Pediatrics, Ss. Cyril and Methodius University in Skopje, Faculty of Medicine, Department for Neonatal Screening, Skopje, North Macedonia, The Republic of; ²University Clinic for Pediatrics, Ss. Cyril and Methodius University in Skopje, Faculty of Medicine, Department for Cystic Fibrosis, Skopje, North Macedonia, The Republic of; ³Ministry of Health, Department for Primary and Preventive Health Care, Skopje, North Macedonia, The Republic of

Objectives: Newborn screening (NBS) allows early diagnosis of cystic fibrosis (CF) and helps parents to keep their child as healthy as possible and delay or prevent serious, lifelong health problems related to this disease. In Macedonia, it was introduced as a national population program in 2019 after a pilot study in 2018.

Methods: Immunoreactive trypsinogen (IRT) was measured in dried blood spots sampled 48 hours after birth, using fluoroimmunoassay (DELFI) during the pilot study in 2018 as well as the period April 2019 – December 2020. Two-step IRT-IRT algorithm is performed, followed by the sweat test for confirmation/exclusion of the CF diagnosis when the IRT values were higher than the cut off values (70 ng/ml and 45 ng/ml, respectively).

Results: A total of 43,139 newborns have been screened for CF during the study period, and overall incidence of 1/2,538 was detected. Recall rate was 0.44% (n = 190). Out of 41 (0.095%) screening positive cases, the diagnosis of CF was confirmed in 17 (0.039%) newborns after the positive sweat test and molecular *CFTR* analysis. Twelve of the detected CF cases were ethnic Albanians (70.6%) and 5 were ethnic Macedonians (29.4%). Moreover, the CF incidence observed among the Albanian neonatal population (1/1284) was 4-fold higher than the incidence detected in the Macedonian newborns (1/4530). The more frequent consanguineous marriages in the Albanian population over the centuries, have probably led to a higher percentage of carriers of the CF mutations among them.

Conclusions: The detected overall CF incidence showed that CF is common in our country. We observed different ethnic distribution of the CF incidence in Macedonia. The estimation of the carriers for the *CFTR* mutations may explain the high CF incidence among the Albanian population.



STEERING COMMITTEE
Isabelle Fajac, FR
Carlo Castellani, IT
Carla Colombo, IT
Francesco Blasi, IT
Mandy Bryon, UK
Carlos Farinha, PT
Carsten Schwarz, DE
Michael Tunney, UK

SCIENTIFIC COMMITTEE
Debbie Baines, UK
Peter Barry, UK
Annamaria Bevivino, IT
Sébastien Boutin, DE
Anna Cereseto, IT
Juliette Champreux, FR
Tom Coenye, BE
Sarah Collins, UK
Domenico Coviello, IT
Damian Downey, UK
Lieven Dupont, BE
Olaf Eickmeier, DE
Emmanuelle Girodon, FR
Andreas Hector, CH
Geneviève Héry-Arnaud, FR
Nataliya Kashirskaya, RU
Ruth Keogh, UK
Marta Kerstan, CH
Bertrand Kleizen, NL
Barry Linnane, IE
Nichola MacDuff, UK
Meir Mei Zahav, IL
Elizabeth Owen, UK
Rita Padoan, IT
Nicoletta Pedemonte, IT
Dario Prais, IL
Ana Filipa Rocha, PT
Dorota Sands, PL
David Sheppard, UK
Michal Shteinberg, IL
Ulrike Smrekar, AT
Stephanie Van Biervliet, BE
Katrien Van Gompel, BE
Marlies Wagner, AT
Jaroslaw Walkowiak, PL

CONFERENCE ORGANISER
European Cystic Fibrosis Society
Kastanieparken 7
7470 Karup, Denmark
Tel.: +45 8667 6260
Fax: +45 8667 6290
E-mail: info@ecfs.eu

CONFERENCE SECRETARIAT
ECFS 2021
Conference Secretariat
c/o K.I.T. Group GmbH
Kurfürstendamm 71
10709 Berlin, Germany
E-mail: ecfs2021@kit-group.org
Fax: +49 30 24 603 267

Registration/Hotel:
Tel.: +49 30 24 603 338

Sponsoring/Satellite Symposia:
Tel.: +49 30 24 603 243

Exhibition Services/ESOS:
Tel.: +49 30 24 603 278

CERTIFICATE OF ATTENDANCE

This is to certify that

Violeta Anastasovska

Attended the

44th EUROPEAN CYSTIC FIBROSIS CONFERENCE
9 – 12 June 2021 / ECFS 2021 Digital Conference

The 44th European Cystic Fibrosis Conference (ECFS 2021 Digital Conference), 9 – 12 June 2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 12 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

We thank you for your participation,



Isabelle Fajac
ECFS President